19,547 Shares in Vera Therapeutics, Inc. $VERA Bought by MFA Wealth Advisors LLC

MFA Wealth Advisors LLC purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,547 shares of the company’s stock, valued at approximately $631,000.

A number of other hedge funds also recently modified their holdings of VERA. Nykredit A S acquired a new stake in Vera Therapeutics in the second quarter valued at $97,000. Strs Ohio acquired a new stake in shares of Vera Therapeutics in the first quarter valued at about $249,000. NINE MASTS CAPITAL Ltd bought a new position in shares of Vera Therapeutics during the second quarter worth about $405,000. Arizona State Retirement System lifted its stake in shares of Vera Therapeutics by 12.3% in the second quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock worth $507,000 after acquiring an additional 1,295 shares during the period. Finally, Sei Investments Co. lifted its stake in shares of Vera Therapeutics by 114.2% in the first quarter. Sei Investments Co. now owns 13,001 shares of the company’s stock worth $523,000 after acquiring an additional 6,932 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Trading Up 2.8%

VERA traded up $0.83 during trading on Wednesday, hitting $30.25. The company’s stock had a trading volume of 3,285,134 shares, compared to its average volume of 1,626,524. The firm has a market capitalization of $2.18 billion, a P/E ratio of -5.16 and a beta of 1.06. Vera Therapeutics, Inc. has a twelve month low of $23.05 and a twelve month high of $56.05. The stock’s fifty day moving average price is $32.91 and its 200-day moving average price is $36.23. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same quarter in the prior year, the business posted ($1.20) earnings per share. Analysts anticipate that Vera Therapeutics, Inc. will post -6.44 EPS for the current year.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total transaction of $684,500.00. Following the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at $8,704,028. This represents a 7.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Wedbush restated a “neutral” rating and set a $34.00 price target on shares of Vera Therapeutics in a report on Monday, August 17th. Needham & Company LLC set a $125.00 price objective on shares of Vera Therapeutics in a research note on Wednesday, July 8th. HC Wainwright decreased their price objective on shares of Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. JPMorgan Chase & Co. boosted their target price on shares of Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a report on Tuesday, September 8th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.15.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s lead product candidate is atacicept, an investigational fusion protein designed to inhibit two immune signaling molecules, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which contribute to the survival and activity of antibody-producing B cells.

Vera is primarily studying atacicept as a potential treatment for immunoglobulin A nephropathy (IgA nephropathy), a chronic kidney disorder caused by the buildup of IgA immune complexes.